BioSpace News Archive

Business

Ipsen to Acquire Albireo for Rare Disease Portfolio

Ipsen bolsters rare disease portfolio with acquisition of liver disease specialist Albireo.

January 9, 2023
·
1 min read
·
George Budwell
Drug Development

Day One Bio to Seek Approval in Pediatric Glioma

Day One Biopharmaceutical reported positive topline data from a Phase II trial in pediatric low-grade glioma, confirming earlier results.

January 9, 2023
·
2 min read
·
Heather McKenzie
Drug Development

Takeda-Arrowhead’s AATD Therapeutic Slightly More Effective Than Placebo in Phase II

Takeda and Arrowhead Pharmaceuticals’ Phase II trial studying fazirsiran, an investigational RNA therapeutic developed for AATD-LD, was effective in Phase II–but so was the placebo.

January 9, 2023
·
1 min read
·
Rosemary Scott
Pharm Country

The Top New York Biopharma Companies Hiring Now

There are plenty of options if you’re looking to make a career move into New York. To help, here are some of the top biopharma companies hiring right now for positions based in New York.

January 9, 2023
·
5 min read
·
Franklin Carpenter
Business

Chiesi Ups Rare Disease Game with $1.48B Amryt Acquisition

Italian biopharma Chiesi Farmaceutici SpA announced Sunday it was acquiring rare disease-focused Amryt Pharma in a deal that could reach up to $1.48 billion in value.

January 9, 2023
·
2 min read
·
Tristan Manalac
Business

Second Neurocrine-Voyager Pact Targets Underlying Cause of Parkinson’s (Updated)

Neurocrine Biosciences and Voyager Therapeutics inked a CNS-targeted collaboration potentially worth a potential $4.4 billion.

January 9, 2023
·
2 min read
·
Kate Goodwin
Drug Development

AstraZeneca Buys CinCor in a Deal Worth Up to $1.8B

The pharma titan adds an intriguing blood pressure medication to its line up with a buyout of CinCor.

January 9, 2023
·
2 min read
·
Tristan Manalac
Business

Twist and Astellas Partner on Antibody Discovery Program

Twist Bioscience announced a partnership with Astellas Pharma on Monday, seeking to discover antibodies against several targets to hit on curative therapies for hard-to-treat diseases.

January 9, 2023
·
1 min read
·
Lisa Munger
Biotech Bay

Rezo Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rezo Therapeutics announced today that Nevan Krogan, Ph.D., co-founder and chief executive officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

January 9, 2023
·
1 min read
Biotech Beach

Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference

Crinetics Pharmaceuticals, Inc. today announced that Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, will provide a company update at the 41st Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 9-12, 2023.

January 9, 2023
·
8 min read